-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US09077D1000 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.38 |
|---|---|
| Market Cap | 6M |
| PE Ratio | None |
| Target Price | 10.5 |
| Dividend Yield | None |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BFRI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025